Valeant Pharmaceuticals Inc. and EyeGate Pharmaceuticals have entered an exclusive, global licensing agreement.
In the agreement, a Valeant subsidiary will have exclusive, worldwide commercial and manufacturing rights for the EyeGate II Delivery System and EGP-437 combination. These products help treat ocular surgery patients that have post-operative pain and inflammation.
"We are pleased to extend our relationship with EyeGate, and to obtain the global commercial and manufacturing rights to the EyeGate II Delivery System for the indication of post-operative inflammation and pain in ocular surgery patients," Valeant CEO and Chairman Joseph Papa said in a statement. "We believe that the product has significant potential in the market as part of our Bausch + Lomb business and applaud EyeGate for a remarkable job in advancing the product's development in both uveitis and cataract surgery."
Stephen From, president and CEO of EyeGate, said this second licensing agreement with Valeant provides an important validation of both the clinical and commercial potential of iontophoretic EGP-437.
Alerts Sign-up